Takeda works for 12 new drug approvals by 2024

Takeda works for 12 new drug approvals by 2024

Takeda is looking at bringing nearly a dozen treatments to the market by 2024. Those treatments are aimed at conditions such as cytomegalovirus infections, a rare disease called Hunter Syndrome and complications of premature birth, Andy Plump, Takeda’s head of R&D, said in an interview with the Boston Business Journal.


Takeda believes these therapies can drive a combined $10 billion in peak sales, the Journal said. 


In September, Takeda published the results of a Phase II study of TAK-620 (maribavir) for cytomegalovirus (CMV). The drug is designed to target a specific CMV protein, which may lead to inhibition of CMV DNA replication and encapsidation, reports


Additionally, Takeda has signed collaborations with multiple companies to advance its drug development programs. The company already struck a multi-year drug discovery deal with Charles River Laboratories. The companies will develop potential drug candidates across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience and rare disease.


Takeda, drugs


 Only weeks prior to the deal with Charles River, Takeda forged a collaboration worth up to $1 billion with Turnstone Biologics to tackle a number of cancer indications using that company’s vaccinia virus platform. The company and Cerevance signed a collaboration to tackle diseases of the gastrointestinal tract that have their roots in the central nervous system.

Plump revealed to the Journal that he did not believe the company’s hemophilia A gene therapy treatment would be a market leader. In fact, he went so far as to say the treatment would probably not even be a contender.


But I don’t think you need to be a frontrunner in a field to really be effective. In fact, I think, sometimes in the world we live in, being the frontrunner can have disadvantages,” he told the Journal.

In its gene therapy pipeline, Takeda is developing TAK-754 for hemophilia A. The asset is currently in a Phase I study. The company also has TAK-748 in preclinical studies for treatment of hemophilia B. As the Journal reported, the company sees a strong future for its gene therapy programs and considers them a future driver of business. 


One year ago, Takeda wrapped up its acquisition of Shire plc, which created one of the largest drug developers focused on rare diseases. Over the past year, the company strived to transform itself into becoming a frontrunner in multiple areas, including cell and gene therapies.